Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 9/20 | 0.50 |
| ▸ | HTR2A | P28223 | 9/20 | 0.50 |
| ▸ | HTR7 | P34969 | 9/20 | 0.50 |
| ▸ | HTR6 | P50406 | 9/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.45 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.45 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31623081 | 1.00 | OPRM1 (0.53) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL2315258 | 0.87 | OPRM1 (0.54) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL4979700 | 0.87 | OPRM1 (0.54) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL31623092 | 0.85 | OPRK1 (0.50) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL5348845 | 0.83 | OPRM1 (0.57) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL23648545 | 0.82 | OPRM1 (0.56) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL4954788 | 0.82 | OPRM1 (0.53) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL1700315 | 0.81 | OPRM1 (0.58) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL1195957 | 0.81 | NR1H2 (0.51) | OPRM1OPRK1OPRL1HTR1AHTR2A | |
| SCHEMBL1195959 | 0.81 | NR1H2 (0.51) | OPRM1OPRK1OPRL1HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021145401-A1 | SPIROHETEROCYCLIC DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC. (JP) | 2021-07-22 | — | — | WO | disclosed |
| EP-3082802-B1 | TRYPTOPHAN-2,3-DIOXYGENASE (TDO) AND/OR INDOLAMINE-2,3-DIOXYGENASE (IDO) INHIBITORS AND THEIR USE | IOMET PHARMA LTD (GB) | 2020-02-26 | — | — | EP | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931347-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160367564-A1 | Pharmaceutical Compound | IOMET PHARMA LTD. (GB) | 2016-12-22 | — | — | US | disclosed |
| WO-2015082499-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2015-06-11 | — | — | WO | disclosed |
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | IRIE OSAMU | 2009-07-23 | — | — | US | disclosed |
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | IRIE OSAMU | 2009-07-23 | — | — | US | disclosed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | disclosed |
| US-7531546-B2 | Spiro-substituted pyrrolo[2,3-D]pyrimidines as cathepsin inhibitors | NOVARTIS AG (CH) | 2009-05-12 | — | — | US | disclosed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2004076455-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | NOVARTIS AG (CH) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367564-A1 | Pharmaceutical Compound | TDO2, IDO1, IDO2 | OPRM1 52/4885OPRK1 67/4885OPRL1 192/4885 |
| US-20090186889-A1 | SPIRO-SUBSTITUTED PYRROLOPYRIMIDINES | CTSS, CTSK, CTSZ | OPRM1 1881/4885OPRK1 58/4885OPRL1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.